Intracoronary compared with intravenous bolus abciximab application during primary percutaneous coronary intervention: Design and rationale of the Abciximab Intracoronary versus intravenously Drug Application in ST-Elevation Myocardial Infarction (AIDA STEMI) trial

American Heart Journal

Volumn 159, Issue 4, 2010, Pages 547-554

  Thiele, Holger ^a   Wöhrle, Jochen ^b   Neuhaus, Petra ^c   Brosteanu, Oana ^c   Sick, Peter ^d   Prondzinsky, Roland ^e   Birkemeyer, Ralf ^f   Wiemer, Marcus ^g   Kerber, Sebastian ^h   Schuehlen, Helmut ⁱ   Kleinertz, Klaus ^j   Axthelm, Christoph ^k   Zimmermann, Rainer ^l   Rittger, Harald ^m   Braun Dullaeus, Rüdiger C ⁿ   Lauer, Bernward ^o   Burckhardt, Wolfgang ^p   Ferrari, Markus ^q   Bergmann, Martin W ^r   Hambrecht, Rainer ^s   Schuler, Gerhard ^a   more..

^a UNIVERSITY OF LEIPZIG   (Germany)

^b UNIVERSITY OF ULM   (Germany)

^c Krankenhaus der Barmherzigen Brüder ^*  (Germany)

^d Krankenhaus der Barmherzigen Brüder   (Germany)

^e Carl von Basedow Klinikum Merseburg   (Germany)

^f Schwarzwald Baar Klinikum Villingen Schwenningen   (Germany)

^g RUHR UNIVERSITY BOCHUM   (Germany)

^h Abteilung Kardiologie   (Germany)

ⁱ Vivantes Auguste Viktoria Klinikum   (Germany)

^j Klinikum Pirna ^*  (Germany)

^k Klinikum Pirna   (Germany)

^l Klinikum Pforzheim GmbH   (Germany)

^m KLINIKUM COBURG   (Germany)

ⁿ OTTO VON GUERICKE UNIVERSITY   (Germany)

^o ZENTRALKLINIK BAD BERKA   (Germany)

^p KLINIKUM NÜRNBERG   (Germany)

^q FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^r DEPARTMENT OF CARDIOLOGY   (Germany)

^s Klinikum Links der Weser   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ALDOSTERONE ANTAGONIST; ANGIOTENSIN 1 RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; HEPARIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; PRASUGREL;

ADULT; AGED; ARTICLE; BLEEDING; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HEART INFARCTION; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THROMBOCYTOPENIA; TREATMENT WITHDRAWAL;

AGED; ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; INJECTIONS, INTRA-ARTERIAL; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 77950221441     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2009.12.038     Document Type: Article

References (32)

1. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction-executive summary. Circulation 110 (2004) 588-636
2. Van de Werf F., Bax J., Betriu A., et al. Management of acute myocardial infarction in patients presenting with persistent ST-segment elevation: the task force on the management of ST-segment elevation acute myocardial infarction of the European Society of Cardiology. Eur Heart J 29 (2008) 2909-2945
3. Lerman A.H., Holmes D.R., Herrman J., and Gersh B.J. Microcirculatory dysfunction in ST-elevation myocardial infarction: cause, consequence, or both. Eur Heart J 28 (2007) 788-797
4. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction. JAMA 293 (2005) 1759-1765
5. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 98 (1998) 2695-2701
6. Mehilli J., Kastrati A., Schulz S., et al. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial. Circulation 119 (2009) 1933-1940
7. Godicke J., Flather M., Noc M., et al. Early versus periprocedural administration of abciximab for primary angioplasty: a pooled analysis of 6 studies. Am Heart J 150 (2005) 1015.e11-1015.e17
8. Maioli M., Bellandi F., Leoncini M., et al. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial). J Am Coll Cardiol 49 (2007) 1517-1524
9. De Luca G., Gibson M., Bellandi F., et al. Early Glycoprotein IIb-IIIa inhibitors in Primary angioplasty (EGYPT) cooperation. An individual patients' data meta-analysis. Heart 94 (2008) 1548-1558
10. Dudek D., Siudak Z., Janzon M., et al. European registry on patients with ST-elevation myocardial infarction transferred for mechanical reperfusion with a special focus on early administration of abciximab-EUROTRANSFER Registry. Am Heart J 156 (2008) 1147-1154
11. Ellis S.G., Tendera M., de Belder M.A., et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 358 (2008) 2205-2217
12. Keeley E.C., Boura J.A., and Grines C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 367 (2006) 579-588
13. Thiele H., Eitel I., Hildebrand L., et al. High-dose N-acetylcystein versus placebo to prevent contrast-induced nephropathy and myocardial reperfusion injury in patients with ST-elevation myocardial infarction undergoing primary PCI. Eur Heart J 29 Abstract Supplement (2008) 9
14. Thiele H., Engelmann L., Elsner K., et al. Comparison of prehospital combination-fibrinolysis plus conventional care with prehospital combination-fibrinolysis plus facilitated percutaneous coronary intervention in acute myocardial infarction. Eur Heart J 26 (2005) 1956-1963
15. Thiele H., Schindler K., Friedenberger J., et al. Intracoronary compared with intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 118 (2008) 49-57
16. Marciniak S.J., Mascelli M.A., Furman M.I., et al. An additional mechanism of action of abciximab: dispersal of newly formed platelet aggregates. Thromb Haemost 87 (2002) 1020-1025
17. Bellandi F., Maioli M., Gallopin M., et al. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention. Catheter Cardiovasc Interv 62 (2004) 186-192
18. Romagnoli E., Burzotta F., Trani C., et al. Angiographic evaluation of the effect of intracoronary abciximab administration in patients undergoing urgent PCI. Int J Cardiol 105 (2005) 250-255
19. The Assessment of the Safety and Efficacy of a New Thrombolytic Regimen (ASSENT)-3 Investigators. Efficacy and safety of tenecteplase in combination with enoxaparin, abciximab, or unfractionated heparin: the ASSENT-3 randomised trial in acute myocardial infarction. Lancet 358 (2001) 605-613
20. The TIMI Research Group. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction. TIMI II A results. JAMA 260 (1988) 2849-2858
21. Schroder R. Prognostic impact of early ST-segment resolution in acute ST-elevation myocardial infarction. Circulation 110 (2004) e506-e510
22. Roberts R., Henry P.D., and Sobel B.E. An improved basis for enzymatic estimation of infarct size. Circulation 52 (1975) 743-754
23. Thiele H., Kappl M.J., Conradi S., et al. Reproducibility of chronic and acute infarct size measurement by delayed enhancement magnetic resonance imaging. J Am Coll Cardiol 47 (2006) 1641-1645
24. Thiele H., Kappl M.J., Linke A., et al. Influence of time-to-treatment, TIMI-flow grades, and ST-segment resolution on infarct size and infarct transmurality as assessed by delayed enhancement magnetic resonance imaging. Eur Heart J 28 (2007) 1433-1439
25. The GUSTO Investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 329 (1993) 673-682
26. Wohrle J., Nusser T., Mayer C., et al. Intracoronary application of abciximab in patients with ST-segment elevation myocardial infarction. EuroInterv 3 (2007) 465-469
27. Pocock S.J. Current issues in the design and interpretation of clinical trials. Br Med J (Clin Res Ed) 290 (1985) 39-42
28. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase 1 findings. N Engl J Med 312 (1985) 932-936
29. Wu K.C., Zerhouni E.A., Judd R.M., et al. Prognostic significance of microvascular obstruction by magnetic resonance imaging in patients with acute myocardial infarction. Circulation 97 (1998) 765-772
30. Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) Investigators. Primary versus tenecteplase-facilitated percutaneous coronary intervention in patients with ST-segment elevation acute myocardial infarction (ASSENT-4 PCI): randomised trial. Lancet 367 (2006) 569-578
31. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 358 (2008) 2218-2230
32. Jolly S.S., Amlani S., Hamon M., et al. Radial versus femoral access for coronary angiography or intervention and the impact on major bleeding and ischemic events: a systematic review and meta-analysis of randomized trials. Am Heart J 157 (2009) 132-140